PRM exhibits a severe divergence between its market price and fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the stock has seen a massive 198% one-year price surge and strong revenue growth of 19.2%, the underlying financials are distressed with an operating margin of -160.74% and negative ROE. The valuation is aggressively stretched with a Price/Sales ratio of 7.61, which is unsustainable for a company with negative profit margins. Combined with bearish insider selling and a failing deterministic health scorecard, the current price appears to be driven by speculation rather than value.